Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesolv
- Development stage
- Phase 3
- Lead developer
- Marinomed Biotech
- Modality
- Small Molecules
- Administration
- Intranasal, Inhalation
01
Overview
Budesolv is a novel formulation of budesonide developed using Marinomed's proprietary Marinosolv technology platform. It's a clear solution nasal spray that delivers the glucocorticoid budesonide at approximately 16% of the dose of conventional suspension-based products while maintaining equivalent efficacy and providing faster onset of action (within 3-4 hours). The product is preservative-free and designed for treating allergic rhinitis.
- Brand names
- Budesolv
- Other names
- MAM-1004-1MAM1004-1MAM 1004-1MAM-1004MAM1004MAM 1004
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on budesolv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesolv.